Financial insights of ERNA

MyFinsight

Home Blog About

|||

Income Overview

Net Income

-$4,017K

EPS

-$3.4

Unit: Thousand (K) dollars

Income Statement

2026-06-30

2026-03-31

2025-12-31

2025-09-30

Revenue

-

0*

-

Cost of revenues

-

0*

-

Gross profit

-

0

-

Gain on lease termination

-

0

-

Research and development

2,792

1,915

676

1,035

General and administrative

1,312

1,631

1,419

958

Impairment of goodwill

-

2,044

-

Total operating expenses

4,104

5,590

2,095

1,993

Loss from operations

-4,104

-5,590

-2,095

-1,993

Change in fair value of convertible notes

-

0*

-

Change in fair value to bridge notes derivative liability

-

0*

-

Change in fair value of contingent consideration

-

0*

-

Forward Sales Contract Expense

-

1,496*

-

Change in fair value of warrant liabilities

-

1*

-

Interest income

-

21*

-

Interest income (expense), net

55

44

-63

31

Loss on extinguishment of contingent liability

41

-

-1,402*

734

Other expense, net

-1

-

479

-6

Total other income (expense), net

95

44

530

759

Loss before income taxes

-4,009

-5,546

-1,565

-1,234

Benefit (provision) for income taxes

-

-40

-62

6

Net loss

-4,009

-5,506

-1,503

-1,240

Series a preferred stock dividend

8

-

8

-

Net loss attributable to common stockholders

-4,017

-

-1,511

-1,240

Basic EPS

-3.4

-6.95

-0.24

-0.15

Diluted EPS

-3.4

-6.95

-0.24

-0.15

Basic Average Shares

1,183,000

792,000

6,307,000*

8,226,000

Diluted Average Shares

1,183,000

792,000

6,307,000*

8,226,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

MyFinsight

Making company financials insightful for everyone

About
Blog
Privacy Policy
Contact

Income Overview

Net Income

-$4,017K

EPS

-$3.4

Unit: Thousand (K) dollars

Income Statement

2026-06-30

2026-03-31

2025-12-31

2025-09-30

Revenue

-

0*

-

Cost of revenues

-

0*

-

Gross profit

-

0

-

Gain on lease termination

-

0

-

Research and development

2,792

1,915

676

1,035

General and administrative

1,312

1,631

1,419

958

Impairment of goodwill

-

2,044

-

Total operating expenses

4,104

5,590

2,095

1,993

Loss from operations

-4,104

-5,590

-2,095

-1,993

Change in fair value of convertible notes

-

0*

-

Change in fair value to bridge notes derivative liability

-

0*

-

Change in fair value of contingent consideration

-

0*

-

Forward Sales Contract Expense

-

1,496*

-

Change in fair value of warrant liabilities

-

1*

-

Interest income

-

21*

-

Interest income (expense), net

55

44

-63

31

Loss on extinguishment of contingent liability

41

-

-1,402*

734

Other expense, net

-1

-

479

-6

Total other income (expense), net

95

44

530

759

Loss before income taxes

-4,009

-5,546

-1,565

-1,234

Benefit (provision) for income taxes

-

-40

-62

6

Net loss

-4,009

-5,506

-1,503

-1,240

Series a preferred stock dividend

8

-

8

-

Net loss attributable to common stockholders

-4,017

-

-1,511

-1,240

Basic EPS

-3.4

-6.95

-0.24

-0.15

Diluted EPS

-3.4

-6.95

-0.24

-0.15

Basic Average Shares

1,183,000

792,000

6,307,000*

8,226,000

Diluted Average Shares

1,183,000

792,000

6,307,000*

8,226,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Ernexa Therapeutics Inc. (ERNA)